Abstract
Background Prisons are high-risk environments for Covid-19. Vaccination levels among prison staff remain troublingly low - lower than levels among residents and members of the surrounding community. The situation is troubling because prison staff are a key vector for Covid-19 transmission.
Objective To assess patterns and timing of staff vaccination in California state prisons and identify individual- and community-level factors associated with being unvaccinated.
Design We calculated fractions of prison staff and incarcerated residents in California state prisons who remained unvaccinated. Adjusted analyses identified demographic, community, and peer factors associated with vaccination uptake among staff.
Setting California Department of Corrections and Rehabilitation prisons.
Participants Custody and healthcare staff who worked in direct contact with residents.
Main Outcomes and Measures Remaining unvaccinated through June 30, 2021.
Results A total of 26% of custody staff and 52% of healthcare staff took ≥1 dose in the first two months of vaccine offer; uptake stagnated thereafter. By June 30, 2021, 61% of custody and 37% of healthcare staff remained unvaccinated. Remaining unvaccinated was positively associated with younger age, prior Covid-19, residing in a community with relatively low vaccination rates, and sharing shifts with co-workers who had relatively low vaccination rates.
Conclusions and Relevance Vaccine uptake among prison staff in California in regular contact with incarcerated residents has plateaued at levels that pose ongoing risks—both of further outbreaks in the prisons and transmission into surrounding communities. Staff decisions to forego vaccination appear to be complex and multifactorial. Achieving safe levels of vaccine protection among frontline staff may necessitate requiring vaccination as condition of employment.
Competing Interest Statement
The Stanford research team has been engaged in conducting Covid 19 related research for the California Department of Corrections and Rehabilitation (CDCR) since April 2020. CDCR provides our team with data to enable this research to be done, but has not provided any funding for the work to date. This work is supported in part by the Covid 19 Emergency Response Fund at Stanford, established with a gift from the Horowitz Family Foundation, a grant from the National Institute on Drug Abuse, a grant from the Centers for Disease Control and Prevention through the Council of State and Territorial Epidemiologists, and a grant from the National Science Foundation Graduate Research Fellowship Program.
Funding Statement
This work is supported in part by the Covid 19 Emergency Response Fund at Stanford, established with a gift from the Horowitz Family Foundation, a grant from the National Institute on Drug Abuse, a grant from the Centers for Disease Control and Prevention through the Council of State and Territorial Epidemiologists, and a grant from the National Science Foundation Graduate Research Fellowship Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Stanford Institutional Review Board approved the study under protocol numbers IRB 55835 and IRB 55671.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Source Supported in part by the Covid-19 Emergency Response Fund at Stanford, established with a gift from the Horowitz Family Foundation; a grant (R37-DA15612), awarded to Dr. Goldhaber-Fiebert and Dr. Salomon, from the National Institute on Drug Abuse; a grant (NU38OT000297-02), awarded to Dr. Salomon, from the Centers for Disease Control and Prevention through the Council of State and Territorial Epidemiologists; a grant (DGE-1656518), awarded to Ms. Chin, from the National Science Foundation Graduate Research Fellowship Program.
Data Availability
The California Department of Corrections and Rehabilitation provided anonymized data which is kept on an encrypted and secure server. The data are not publicly available.